REST Study
In 2010, Ibn Al-Haytham led REST, a post-marketing observational study evaluating the efficacy, safety, and tolerability of REVOSYL in managing essential hypertension—not in theory, but in actual clinical practice across Syria.
Study Scope1:
Patients: 1959
Participating Doctors: 141
Setting: Diverse outpatient environments across the country
Efficacy Rating:
88.4 Controlled
11.6 Uncontrolled
Tolerability Ratings1:
94.6% Excellent &Good
5.4% Fair& Poor
Adverse Event Probability: 5.1%
This study didn’t just measure molecules—it measured lives impacted, trust earned, and clinical realities navigated.
At Ibn Al-Haytham, we believe that credibility isn’t claimed—it’s demonstrated through transparent data, regional relevance, and patient-first insights.